Kite to Leverage HalioDx’s Immunoscore® Solutions to Understand Tumor Microenvironment and Guide Cancer Cell Therapies Development
HalioDx, the immuno-oncology diagnostic company today announced an extended strategic collaboration with Kite, a Gilead company, a world leader in CAR-T cell therapy.
Fruit of a first productive partnership between the two companies, this extended Strategic Collaboration aims at developing and validating immune-based biomarkers for Kite’s investigational therapies. The collaboration structure covers multiple blood cancer and solid tumor indications and relies on the Immunoscore® platform. The collaboration also includes the Immunogram by HalioDx, a “360°” approach based on the understanding and the analysis of the immune microenvironment of tumors providing a personalized and dynamic “fingerprint” of tumor-immune system interaction, and the Cancer Immune Atlas which produces, in a selected indication, statistically and biologically significant conclusions from large data sets of multiple biomarkers.
“We look forward to strengthen our collaboration with Kite. We feel confident that this extended partnership will allow both companies to scale up our respective immune biomarker approach and expand from DLBCL to other tumor types” said Vincent Fert, CEO of HalioDx.
“The two teams have been working closely since 2016 with some tangible results presented at AACR and ASCO outlining potential predictive value of Immunoscore® and Immunosign® within ZUMA 1 clinical trial” said Corinne Danan, EVP Pharma Business Unit of HalioDx. “Our first studies have highlighted the relevance of the HalioDx’s multimodal Immunogram approach. Our extended collaboration will enable us to further validate these data but also to expand the benefits of this approach beyond blood cancers”.
Financial details on the agreement with Kite are not disclosed.
 DLBC, Diffuse Large B Cell Lymphoma.